Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma [6]

New England Journal of Medicine

Volumn 345, Issue 23, 2001, Pages 1711-1712

  Pantuck, A J ^a   Belldegrun, A S ^a   Figlin, R A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; KIDNEY CARCINOMA; LETTER; MAJOR CLINICAL STUDY; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; SURVIVAL ANALYSIS;

EID: 0035818938     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200112063452317     Document Type: Letter

References (3)

1. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
2. Tumor nephrectomy plus Interferon α is superior to Interferon alpha; alone in metastatic renal cell carcinoma
3. The natural history of metastatic renal cell carcinoma: A computer analysis